These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18397345)

  • 21. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
    Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
    Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
    Hideshima T; Mitsiades C; Akiyama M; Hayashi T; Chauhan D; Richardson P; Schlossman R; Podar K; Munshi NC; Mitsiades N; Anderson KC
    Blood; 2003 Feb; 101(4):1530-4. PubMed ID: 12393500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
    Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
    Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
    Bai QX; Zhang XY
    Int J Mol Sci; 2012; 13(4):4831-4838. PubMed ID: 22606012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2024 Sep; 43(40):3018. PubMed ID: 39209967
    [No Abstract]   [Full Text] [Related]  

  • 32. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
    Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
    Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
    Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
    Kim JE; Lee JI; Jin DH; Lee WJ; Park GB; Kim S; Kim YS; Wu TC; Hur DY; Kim D
    Oncol Rep; 2014 May; 31(5):2429-37. PubMed ID: 24627094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 36. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption.
    Kim YG; Kang JH; Kim HJ; Kim HJ; Kim HH; Kim JY; Lee Y
    J Dent Res; 2015 Sep; 94(9):1243-50. PubMed ID: 26130255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.